HR-1266-119
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 623.
Sponsored by Jimmy Panetta (D-CA)
What it does
This bill would add xylazine (an animal sedative increasingly mixed into illicit street drugs) to Schedule III of the Controlled Substances Act, creating federal tracking, registration, and recordkeeping requirements for its manufacture and distribution. It would create special rules allowing veterinarians and authorized users to dispense and possess it for animal use without full registration, delay certain security and labeling requirements for manufacturers and practitioners, add xylazine to the DEA's drug tracking system (ARCOS), and direct the Sentencing Commission and DEA to study and report on illicit xylazine use.
Who benefits
Veterinarians and legitimate animal-care users who retain streamlined access to xylazine; law enforcement and public health agencies seeking better data on xylazine-linked overdoses; existing xylazine manufacturers who receive a delayed compliance timeline and exemption from new security capital expenditures; communities affected by xylazine-adulterated opioids ("tranq") who may benefit from improved tracking and prosecution tools.
Who is hurt
Individuals who illegally divert, distribute, or possess xylazine outside veterinary channels, who would now face federal controlled-substance penalties; practitioners and distributors who must comply with new registration, recordkeeping, and eventual labeling requirements, incurring administrative costs; people whose xylazine possession does not fit the bill's narrow "ultimate user" exceptions, who could face new registration burdens or legal exposure.
Supporters argue
Supporters argue that xylazine, often called "tranq," has become a widespread adulterant in illicit fentanyl supplies linked to severe skin wounds and overdose deaths, and that Schedule III classification would give the DEA and law enforcement tools to track diversion and prosecute illicit trafficking. They contend the bill carefully preserves legitimate veterinary access through tailored exemptions and phased compliance deadlines, avoiding disruption to animal care while closing a regulatory gap that traffickers have exploited.
Opponents argue
Opponents argue that scheduling xylazine could create new administrative burdens and compliance costs for veterinarians, wildlife programs, and manufacturers, potentially reducing access to a drug still needed for legitimate animal care, especially in rural or under-resourced practices. They contend that criminal scheduling approaches to drug adulterants have historically had limited success curbing illicit supply chains, and that increased criminal penalties may disproportionately affect low-level offenders rather than large-scale traffickers.
Constitutional context
Congress's authority to schedule controlled substances rests on the Commerce Clause, as affirmed in Gonzales v. Raich (2005), which upheld federal regulation of controlled substances even in intrastate contexts. The bill does not raise novel constitutional questions beyond this established scheduling authority.
Checks and balances
Congress directs the scheduling change and reporting requirements; the DEA, FDA, and Attorney General implement and enforce them administratively; the independent Sentencing Commission retains discretion over guideline amendments, subject to congressional oversight.
Historical precedent
Congress has previously scheduled emerging adulterants and analog substances, such as fentanyl analogues under the SUPPORT Act (2018) and the temporary fentanyl-related substance scheduling extensions, following similar patterns of adding tracking and registration requirements.